Takis’ Post

Our CEO, Iain Kilty, recently joined Jim Cornall on Beyond Biotech—the #podcast from Labiotech.eu—to dive into Sitryx’s pioneering work in immunometabolism. From his journey to CEO to Sitryx’s innovative approach to immunometabolism, Iain shares how targeting metabolic pathways have the potential to reset immune responses, moving beyond antibody-based therapies and earlier immunosuppression treatments. By focusing on the specific needs of immune cells, Sitryx is opening new pathways to treat autoimmune and inflammatory diseases and drive sustained disease remission. Don’t miss the #episode: https://lnkd.in/dz4b3Yea #Biotech #Immunology #PrecisionImmunology #DrugDiscovery #DrugDevelopment #Biotechnology

Excited to be attending World Vaccine Congress Europe in Barcelona this week! Kicked off yesterday with pre-Congress workshops on how the world can prepare for Biothreats and Disease X in the morning, and then Vaccine Equity in the afternoon. Key takeaways were: - One world, one dossier through harmonizing regulatory requirements - Creating a global framework to deliver regulatory enabling data as quickly as possible will help achieve the goal of having a vaccine ready within 100 days of the emergence of a new pandemic threat. - CEPI has identified 3 priority platforms to have in place as advanced prototypes for future pandemics - viral vectors, protein subunits and mRNA - Vaccine equity = getting the right vaccine to the right person at the right time. Engagement to build trust in new technologies is an essential part of equitable development and should be incorporated across the whole translational pathway, as well as ongoing monitoring post-launch and rapid response to mitigate any identified risks. Quote of the day “To achieve vaccine equity, we need to be driven by values not capitalism.” Definitely a place for Academia to deliver here! #UniServices

📘 New publication! CARB-X Chief of R&D Erin Duffy, PhD, and Alliance Director Ed Buurman, PhD, MBA, worked alongside other antibiotic resistance experts to develop a Vaccine Value Profile for Klebsiella pneumoniae, a major cause of hospital-acquired infections such as pneumonia, bloodstream infections, infections in newborn infants, and intensive-care unity patients. The Vaccine Value Profile provides a high-level, holistic assessment of K. pneumoniae to inform the potential public health, economic, and societal value for K. pneumoniae vaccines as well as other preventatives and therapeutics. The World Health Organization has identified K. pneumoniae on its priority pathogens list, requiring critical prioritization of funding and incentives as well as research and development to address this drug-resistant bacteria. 🔗 Read more: https://bit.ly/3IVVs9S

 🌟🌟🌟 Exciting News from Clinbridge Biotech! 🌟🌟🌟 Clinbridge Biotech is proud to announce our participation in The 7th World Congress on Infectious Diseases (WCID 2024), taking place from October 24th to 26th in Baltimore, Maryland, USA. This landmark annual event gathers renowned experts and academic/industry leaders in infectious disease and I&I research, and we are thrilled to be part of it. Our Founder and CSO, Dr. WenQing Yang, who has served on the scientific committee of this conference for several years, will deliver a keynote presentation titled: “Fueling Drug Research and Development Process with Patient-Centric and Clinically Relevant Animal Models.” This presentation will highlight the critical role of patient-centric, clinically relevant animal models in advancing drug discovery and development, a cornerstone of our work at Clinbridge Biotech. We are committed to pushing the boundaries of innovation and improving translational research to bring meaningful advances to patients. With Dr. Yang’s extensive involvement in the conference over the years, we look forward to contributing to discussions that will shed light on the future of infectious disease and I&I research. Join us in WCID 2024! Together, we can drive the future of science and innovation. #WCID2024 #ClinbridgeBiotech #InfectiousDiseases #DrugDevelopment #PatientCentric #Innovation #TranslationalResearch #AnimalModels #Baltimore

📢 Weekly Top 5 Must-Read News in Market Access Today | 4-8 November Highlights in Health Sciences! Welcome to 4-8 November of our weekly newsletter series, where we bring you the most critical updates in market access, healthcare, and pharmaceuticals! Each week, we’ll highlight the top 5 stories making waves in the industry. In this first edition, delve into the collaborative global efforts advancing mpox vaccine trials 🧬, the transformative power of targeted therapies for rare cancers 💊, and AstraZeneca's latest innovations in infectious disease, showcased at IDWeek 2024 🦠. We also explore the shift among Austrian youth towards modern nicotine alternatives and introduce CHEERS-AI, a groundbreaking framework evaluating AI's economic impact in healthcare. Stay informed on these pivotal developments with our weekly insights—and don't miss future issues to keep up with everything happening in health sciences! Explore the full articles through the links below: 1️⃣ Coordinated Mpox Vaccine Trials Initiative: https://lnkd.in/dZgSGfwX 2️⃣ Hopeful Advances in Rare Blood Cancer Treatments: https://lnkd.in/dqiXUAFR 3️⃣ AstraZeneca’s IDWeek 2024 Innovations in Infectious Diseases: https://lnkd.in/dbiVZBUP 4️⃣ Austria’s Youth Shift to Alternative Nicotine Products: https://lnkd.in/eA4u6s9s 5️⃣ CHEERS-AI: Economic Impact of AI in Healthcare: https://lnkd.in/eM-StUZ9 #MarketAccess #Healthcare #Pharma #Innovation #AI #WeeklyHealthUpdates

Boost your detection of antigen-specific B cells with dual staining! 🌟 In the rapidly evolving field of antibody-based immunotherapies, accurate detection of antigen-specific B cells is key. Klickmer® is now available with BV421 in addition to FITC, PE, and APC, providing more options for dual staining of antigen-specific B cells. This enables reliable B cell analysis using flow cytometry with minimal background interference. Klickmer® technology can easily be conjugated with mono-biotinylated molecules of your choice for tailored B cell detection. In a recent study, we assembled Klickmer® BV421 and PE reagents with SARS-CoV-2 spike proteins for longitudinal detection and phenotyping of antigen-specific B cells after vaccination. Read more about the study by following the link in the comments! 👇👇 #Bcells #flowcytometry #antigenspecificity #immunophenotyping #Fluorophores

Calling all Vaccine Researchers! 📢 Join the Joint PSI/EFSPI Vaccine SIG Webinar on Statistical and Mechanistic Models for Correlates of Protection (CoPs)! This webinar dives into two key approaches to CoPs in vaccine development: - Statistical models: Learn how to use quantitative frameworks to identify and validate potential CoPs. - Mechanistic models: Gain insights into the biological mechanisms behind immune responses and protection. By integrating these approaches, you'll gain a deeper understanding of the immunological factors associated with vaccine efficacy and optimize your vaccine clinical trial design. Find out more here: https://zurl.co/mTu3

Calling all Vaccine Researchers! 📢 Join the Joint PSI/EFSPI Vaccine SIG Webinar on Statistical and Mechanistic Models for Correlates of Protection (CoPs)! This webinar dives into two key approaches to CoPs in vaccine development: - Statistical models: Learn how to use quantitative frameworks to identify and validate potential CoPs. - Mechanistic models: Gain insights into the biological mechanisms behind immune responses and protection. By integrating these approaches, you'll gain a deeper understanding of the immunological factors associated with vaccine efficacy and optimize your vaccine clinical trial design. Find out more here: https://zurl.co/mTu3

Learn about AI-based prediction of epitope specificity from bulk AIRR- seq data. iRepertoire is partnering with ImmuneWatch DETECT, the leading TCR antigen specificity software for discovering disease relevant clonotypes and therapeutic TCR immunomonitoring.  Tell us about your research and be among the first to leverage this service to advance your clinical research studies. Contact us at https://hubs.li/Q02TPyfV0 #Immunology #ImmuneWatch #AdaptiveImmuneSystem #Tcell #Epitope #ImmuneRepertoire #AIImmunology

Did you know our Anellovectors can be engineered to have an expanded payload capacity beyond natural anellovirus genome sizes? Data presented at #ASGCT2024 unveiled the broadened therapeutic potential of this novel class of viral vectors across a wide range of disease areas. Learn how we’re advancing the next generation of programmable medicines here: https://bit.ly/47wjJio